The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial.

Noriko SagawaShinji OhnoTakahiro HiratsukaNaoto KondoHiroji IwataHiroko BandoTetsuji OhyamaMayumi IshidaYohei KonoKentaro NakajimaShinichiro EmpukuSetsuko NishikawaYoshiko IrieMasafumi InomataSeigo Kitano

Published in: Breast cancer research and treatment (2019)

UMIN000014840.

Keyphrases

phase ii
clinical trial
open label
double blind
placebo controlled
oxidative stress
diabetic rats
high glucose
phase iii
study protocol
drug induced
anti inflammatory
cross sectional
randomized controlled trial